Trelanserin

Trelanserin ( ; developmental code name SL 65.0472) is a dual serotonin 5-HT 1B receptor antagonist and serotonin 5-HT 2A receptor antagonist which was under development for the treatment of peripheral arterial occlusive disorders and…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Trelanserin ( ; developmental code name SL 65.0472) is a dual serotonin 5-HT 1B receptor antagonist and serotonin 5-HT 2A receptor antagonist which was under development for the treatment of peripheral arterial occlusive disorders and thrombosis but was never marketed. It is taken orally. The drug was under development by Sanofi-Aventis.

It reached phase 2 clinical trials prior to the discontinuation of its development in 2009. Trelanserin was first described in the scientific literature by 2000.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1333531397 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.